Affymax, Takeda launch OMONTYS injection in US

Affymax and Takeda Pharmaceutical Company have announced the availability of OMONTYS injection to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

The once-monthly erythropoiesis-stimulating agent (ESA) for anemia is co-marketed by Affymax and Takeda Pharmaceuticals USA (TPUSA) and distributed by TPUSA.

Affymax chief executive officer John Orwin said, “Today’s announcement represents an important milestone in the field as nephrologists and anemia nurses will now be able to use the first once-monthly treatment for anemia for adult dialysis patients available in the United States.”

TPUSA president Douglas Cole said, “In partnership with Affymax, we will support the providers and physicians as they convert their adult CKD patients on dialysis to OMONTYS.”

OMONTYS is administered either intravenously (IV) or subcutaneously (SC) as a single monthly injection.